Key result
Lower extremity arterial disease prevalence increased from 5% in women aged 60-69 to >25% in those ≥90, with smokers having twice the risk of LEAD compared with nonsmokers.
Why the study?
Are cardiovascular disease risk factors and estrogen use associated with lower extremity arterial disease in community-dwelling postmenopausal women?
Cross-Sectional (n=826)
Are cardiovascular disease risk factors and estrogen use associated with lower extremity arterial disease in community-dwelling postmenopausal women?
Lower extremity arterial disease is common in older women and is associated with modifiable cardiovascular risk factors, with estrogen use showing a potential protective effect that may be mediated by lipoproteins.
High LEAD prevalence with age and doubled smoking risk in older women warrants vigilance; leaves optimal screening and estrogen effects open pending prospective data.
Most studies of lower extremity arterial disease (LEAD) have not included women. To study the frequency of LEAD and its association with cardiovascular disease risk factors and estrogen use in community-dwelling postmenopausal women, we conducted a cross-sectional study of LEAD in 826 women whose average age was 74 years. Cardiovascular disease risk factors and medical history, body mass index (BMI), blood pressure, glucose tolerance, lipids and lipoproteins, and current and past medication use were determined using a standard protocol. Ankle-brachial artery index (ABI) of systolic blood pressure was measured by a trained technician using Doppler ultrasound. LEAD was defined as ABI <0.8. LEAD prevalence increased with age from nearly 5% in the 60-69-year-old group to >25% in women aged 90 and older. In age-adjusted analyses, women with LEAD had significantly lower levels of high-density lipoprotein (HDL) cholesterol, were less likely to exercise regularly, and were less likely to have ever used estrogen replacement therapy. They also had significantly higher levels of blood pressure, low-density lipoprotein (LDL) cholesterol, triglycerides, glucose, and insulin. In multivariate analyses, high HDL cholesterol, regular exercise, and estrogen use were each associated with a reduced risk of LEAD, whereas age, high blood pressure, and abnormal glucose tolerance were each associated with increased risk. Few women (6%) were smokers, but they had twice the risk of LEAD compared with nonsmokers. Estrogen was independently associated with LEAD in a model containing all covariates except LDL and HDL, and this association was no longer significant in a second model adjusting for these lipoproteins. LEAD is common in older women and associated with modifiable risk factors. The apparent protection associated with estrogen should be studied in clinical trials.
No takes yet. Share an insight, caveat, or question.
Morton et al. (2000) conducted a cross-sectional in Lower extremity arterial disease (LEAD) (n=826). Cardiovascular risk factors and estrogen use vs. Absence of risk factors or non-users was evaluated on Lower extremity arterial disease (ABI <0.8). Lower extremity arterial disease prevalence increased from 5% in women aged 60-69 to >25% in those ≥90, with smokers having twice the risk of LEAD compared with nonsmokers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: